Over 1.8 million nonprofits and charities for donors, volunteers and funders

Claim This Nonprofit

More Info

Add to Favorites

Share this Nonprofit

Donate

Volunteering Oportunities

Nonprofit Overview

Causes: Government & Public Administration, Health, Medical Research, Mental Health, Mental Health Treatment

Mission: Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS furthers its mission by: -Developing psychedelics and marijuana into prescription medicines -Training therapists and working to establish a network of treatment centers -Supporting scientific research into spirituality, creativity, and neuroscience -Educating the public honestly about the risks and benefits of psychedelics and marijuana MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

Results: MAPS has completed two Phase 2 FDA studies using MDMA-assisted psychotherapy to treat PTSD, and is in the process of four other similar studies. MAPS also has a study looking at LSD-assisted psychotherapy for treating end-of-life anxiety, an outcome study of the benefits of ibogaine for opiate dependence, and a protocol to investigate medical marijuana to relieve symptoms of PTSD.

Target demographics: Any person whose life may be aided by the transformative nature of psychedelic psychotherapy

Geographic areas served: Worldwide

Programs: Maps' primary focus is research into mdma-assisted psychotherapy ($1,094,575), especially phase 2 research into mdma-assisted psychotherapy in subjects with chronic, treatment-resistant ptsd. In this fiscal year, maps treated the 18th subject in our charleston, south carolina mdma/ptsd study in 24 veterans, firefighters and police officers. An 8th subject was treated in our study in boulder, colorado for people suffering from ptsd from any source, a fourth subject was treated in our mdma/ptsd study in beer yaakov, israel, and an irb approved the amendments for our mdma/ptsd study in vancouver, canada. A 7th therapist participated in our mdma-assisted psychotherapy therapist training study. In addition to our core clinical research, this fiscal year we began planning a series of studies in collaboration with researchers who work with the u. S. Department of veterans affairs' national center for ptsd. We'll be exploring the use of mdma along with more traditional psychotherapeutic methods for treating ptsd including cognitive-behavioral conjoint therapy, cognitive processing therapy, and prolonged exposure therapy. We also began our study looking at the safety and efficacy of using mdma-assisted therapy for anxiety in adults on the autism spectrum and began preparations for a study of mdma-assisted psychotherapy for end-of-life anxiety. These studies will grow significantly in the coming year. Mdma-study related program expenses include costs of video data storage and streaming systems development, budgeting, contracting, and meetings; the costs of developing the treatment manual; training therapists; blinded therapist adherence training; and costs of reviewing and documenting all published mdma literature. There are also mdma-study related supervision of therapists, presentation of our data at professional conferences, and costs to manage the mdma purchased early in our work and to secure the drug for phase 3 trials expected to begin in 2016. Clinical research general costs cover the development of the infrastructure needed for our mdma clinical trials, including work with communications and fundraising departments, staff professional development and conferences, and video streaming and statistical software. Most of the clinical research expenses are personnel, including personnel at each study site: principal investigators, co-investigators, independent raters, overnight physicians, attendant, and study coordinators, as well as maps' internal staff: the clinical director, research associates, information specials, data coordinators and statistical consultants. Ibogaine research expenses were dedicated to completing our studies in mexico ($3,816), and new zealand ($6,329). Lsd research expenses ($12,185) were primarily used for the march 2014 publication of our lsd end-of-life anxiety article in the journal of nervous and mental disease. Marijuana research ($14,905) covered the costs of developing the protocol for a pilot study in which marijuana will be tested to manage symptoms in 76 veterans with chronic, treatment-resistant ptsd, and our efforts to end the public health service (phs) review and the national institute of drug abuse (nida) monopoly of the sale of marijuana for clinical research.

education expenses include harm reduction, events, publications and communications programs. Our zendo project provides a supportive space for people undergoing difficult psychedelic experiences in order to help turn those experiences into opportunities for learning and personal growth, and to reduce the number of drug-related psychiatric hospitalizations and arrests. Services were provided at five major events in fiscal year 2014: burning man (black rock city, nv), envision (costa rica), afrikaburn (south africa), bicycle day (san francisco, ca), and lightning in a bottle (bradley, ca). In order to share recent findings and to inspire existing and new support, maps produced events on psychedelic and marijuana research in colorado, vancouver and santa cruz; and attended more than 17 events that others produced, providing speakers, exhibits, sales of books and maps bulletins, and free distribution of clinical protocols and articles from peer-reviewed journals. Communications included publishing three maps bulletins, and 12 email newsletters, maintaining maps. Org, mdmaptsd. Org, mapscanada. Org, psychedelicscience. Org, and launching mdma-autism. Org. Maps produced "manifesting minds," with north atlantic books, reprinted albert hofmann's "lsd: my problem child," and began work with stanislav grof on his new book, "the visionary world of h. R. Giger. " in spring 2014, maps offered its first webinar, "psychedelic science," in collaboration with evolver learning labs. Maps saw significant growth in coverage of its work in social, online, and traditional media. Maps. Org had 511,449 unique visits and 1,809,246 page views. Facebook likes more than doubled to 89,282. Twitter followers increased 140%, to 17,099. Youtube subscriptions increased 256% to 5,313. Maps received 344 unique media mentions from online and print publications with significant reach. Media outlets include the los angeles times, the new york times, the san francisco chronicle, reason, scientific american, cnn, usa today, msnbc, time, associated press, fox news, forbes, nbc news, playboy, santa cruz sentinel, tricycle, business insider, npr, vice, and southern california public radio (kpcc).

this year, maps operationalized its long-running fiscal sponsorship program, clarifying and updating contracts, process, and structure. This program supports projects that are in alignment with maps mission and vision by offering donors a way to give to a 501(c) 3 nonprofit organization. Maps monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Community Stories

285 Stories from Volunteers, Donors & Supporters

2

General Member of the Public

Rating: 5

I support MAPS because I believe wholeheartedly in the benefits of psychedelics if used purposefully and mindfully as tools for healing. As a 25 year old who has suffered from OCD, PTSD and depression for much of their life, and having tried different medications and psychotherapies with only short term relief that came with many side effects, it was only after my first use of LSD in a healing environment (a forest, with loved ones), did I truly feel capable of understanding and approaching complete management and recovery. I understood my own reality and experiences in a way I had never done so before. The same (although slightly different) profound healing moments occurred with MDMA, psilocybin and mescaline. I have and only will go on these journeys a handful of times in my life, but that is all that is needed. If you truly desire release from your demons and are willing to hold onto the lessons that psychedelics have to offer, I fully believe that they are capable of assisting you greatly. Thank you, MAPS, for raising awareness and conducting research into the benefits of these fascinating chemical angels.

1

General Member of the Public

Rating: 5

I'm personally living with ptsd, social anxiety, anxiety and panic disorder. On the outside I try and look appear and act as normal as could be, but little do people know my battle internally with just trying to convince myself to remain living. Pharmaceuticals do NOT help me nor several others I know who suffer in silence. It's way past the time for better research and better options.

General Member of the Public

Rating: 5

The need for new and innovative techniques to tackling a variety of mental health problems is now needed more than ever! The stresses of everyday existence and the increase in technological advances has brought about more mental health issues than ever before. It's great to see that organistations like this are using alternative tools which generate great results! Keep up the good work MAPS, hopefully one day I'll even be able to join you in making psychedelic studies mainstream and accepted within society.

3

General Member of the Public

Rating: 4

The PTSD pharmaceuticals didn't work. Some made it much worse. Cannabis saved my life. I'll never go back to the poisons!

Thank you MAPS for fighting to end this ignorant/corrupt drugwar!

2 Mekael D.

General Member of the Public

Rating: 5

The front runners in a movement that will be one of the largest global shifts towards a better world. There are so many ways in which our society is suffering (psychologically, emotionally, spiritually), usually involuntarily, and we are left with inadequate tools and outdated information to address these very serious issues. MAPS is dedicated to moving culture beyond the fear of the "War on Drugs" days to an educated, brighter and healthier tomorrow.

Anoob559

General Member of the Public

Rating: 5

Aids me in feeling comfortable that the future is in good hands !! These proteins aid in being in one place. At a time. For being lost in time behind the eyelid of the minds. One can't say I'm blind just need a couple of dimes worth of your time?? Jah bless ~n~ aya be with you!!

General Member of the Public

Rating: 5

MAPS je jedina asocijacija na svetu koja se bavi istraživanjem ogromnih potencijala psihodeličnih i enteogeničnih supstanci na ovaj način i zbog toga zaslužuje da bude proglašena najboljom besprofitnom asocijacijom. Ovom svetu je pod hitno potrebna promena kojoj MAPS pokušava da doprinese na jako profesionalan način.

1

General Member of the Public

Rating: 5

The first LSD experience I had was like loosing my virginity! I feel these drugs have profound psychiatric uses that can help people in many ways

1

General Member of the Public

Rating: 5

If we don't research psychedelics & neurotransmitters more thoroughly we will never understand & cure mental diseases that severely impair people in their lives.

1

General Member of the Public

Rating: 5

現代社會精神問題越來越多,以及越來越多特殊疾病出現,我認為,迷幻藥物的研究非常重要的原因,其一是可以研究出,是否社會誤解那些物質了,其二是他們帶來的醫療效益如果不被蓄意濫用,管理得當,可以讓更多人有活下去的希望,如果社會依舊對這些致幻物質有偏見,而實際上它們對人類社會幾乎是沒有危害,那政府是不是該全面禁止菸酒了,菸酒對人類帶來的危害還比較大呢,至於有害的物質,當然該加以防止,不過確認有藥用價值,依然可以在管制下進行醫療行為。我對你們的研究很支持,希望更多人可以知道你們的研究對人類貢獻多大。